IGF2BP3 and central nervous system cancer: We first evaluated the protein levels of IGF2BP3 in a series of clinical specimens, including nine glioma tissues (three specimens each from WHO grade 2,3,4 groups) and three peritumoral normal tissue using immunohistochemistry.